SCPL9 Antibody

The following FAQs address key methodological and analytical challenges in working with antibodies targeting proteins like C9/Cas9 (presumed context based on search results), focusing on academic research rigor. Questions are categorized into basic and advanced tiers, with evidence-based solutions derived from published studies.

Advanced Research Questions

How to mitigate pre-existing adaptive immunity against bacterial-derived proteins (e.g., Cas9) in therapeutic applications?

• Pre-screening: Use ELISAs or T-cell activation assays to detect anti-Cas9 antibodies/T cells in patient serum (78% of donors had anti-SaCas9 antibodies; 67% had SpCas9-reactive T cells) .

• Ortholog substitution: Switch to Cas9 variants with lower seroprevalence (e.g., FnCas9) to evade immune detection .

How to resolve structural variability in antigen-antibody interactions?

Addressing contradictory data across antibody-dependent assays

• Multi-method validation:

  • Compare immunoblot, immunofluorescence, and IP-MS results.

  • Use CRISPR-edited knockout controls to confirm on-target effects .

• Commercial antibody vetting: Only 18% of tested anti-C9ORF72 antibodies passed specificity criteria, underscoring the need for independent validation .

Methodological Tables

Table 1: Antibody Validation Workflow

Table 2: Strategies for Data Discrepancies